Fuji Pharma Co Ltd
TSE:4554
Net Margin
Fuji Pharma Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Fuji Pharma Co Ltd
TSE:4554
|
32.2B JPY |
7%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
765.4B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
209.1B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.8B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.7B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
203.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.7B USD |
13%
|
Fuji Pharma Co Ltd
Glance View
Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Fuji Pharma Co Ltd's most recent financial statements, the company has Net Margin of 6.5%.
You don't have any saved screeners yet